This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview
  • Pre-Assessment
  • Activity
  • Post-Test
  • Evaluation
  • Claim Credit
Novel Targeted Agents in the Management of Recurrent Advanced Ovarian Cancer

Novel Targeted Agents in the Management of Recurrent Advanced Ovarian Cancer

Format

Webcast

Time to Complete

1 hour

Released

May 23, 2019

Expires

May 23, 2020
Add to Queue


Maximum Credits

1.00 / AMA PRA Category 1 CreditTM

Accredited Provider



This activity is provided by the Johns Hopkins University School of Medicine.

Commercial Supporter

This activity is supported by independent educational grants from AstraZeneca and Tesaro, Inc.

Program Description

Ovarian cancer is the fifth most common cause of cancer death in women in the United States. The majority of patients with ovarian cancer experience disease recurrence and receive second-line and sometimes several lines of therapy. Recurrent ovarian cancer is often resistant to chemotherapy, thus limiting the treatment options. Advances in technology and medical research have identified VEGF and PARP as targets for therapy, leading to the development of antiangiogenesis agents and PARP inhibitors. This activity will examine novel targeted therapy for recurrent advanced ovarian cancer.

Intended Audience

This activity is intended for oncologists, gynecologists, and other clinicians including nurse practitioners (NPs), physician assistants (PAs), and nurses who encounter patients with ovarian cancer.

Educational Objectives

Upon completion of this educational activity, participants should be able to:

  • Discuss the role of angiogenesis inhibitors in the management of recurrent advanced ovarian cancer.
  • Discuss the role of homologous recombination (HR) deficiency in the development of recurrent advanced ovarian cancer.
  • Describe the mechanism of action, efficacy, and safety of PARP inhibitors approved to treat advanced ovarian cancer.
  • Outline the management of patients with recurrent advanced ovarian cancer by incorporating angiogenesis inhibitors or PARP inhibitors into a management program.
  • Outline strategies for engaging patients about PARP inhibitor use to promote adherence to therapy.

Policy on Speaker and Provider Disclosure

It is the policy of the Johns Hopkins University School of Medicine that the presenter and provider globally disclose conflicts of interest. The Johns Hopkins University School of Medicine OCME has established policies in place that will identify and resolve all conflicts of interest prior to this educational activity. Detailed disclosure will be made prior to presentation of the education.

Disclosure Policy

As a provider approved by the Accreditation Council for Continuing Medical Education (ACCME), Johns Hopkins University School of Medicine Office of Continuing Medical Education (OCME) requires attested and signed global disclosure of the existence of all financial interests or relationships with commercial interest from any individual in a position to control the content of a CME activity sponsored by OCME.

The following relationships have been reported for this activity:

Stephanie L. Wethington, MD, MSc, has disclosed she is Principal Investigator on a research grant funded by AstraZeneca.

No one else in a position to control the content of this educational activity has disclosed a relevant financial interest or relationship with any commercial interest.

NOTE: Grants to investigators at the Johns Hopkins University are negotiated and administered by the institution which receives the grants, typically through the Office of Research Administration. Individual investigators who participate in the sponsored project(s) are not directly compensated by the sponsor, but may receive salary or other support from the institution to support their effort on the project(s).

FACULTY PRESENTER AND COURSE CHAIR

Stephanie L. Wethington, MD, MSc
Assistant Professor of Gynecology and Obstetrics
Johns Hopkins University School of Medicine
Baltimore, Maryland

ADDITIONAL CONTENT DEVELOPMENT FACULTY

Andrea R. Hagemann, MD, MSCI
Associate Professor of Obstetrics and Gynecology
Washington University School of Medicine
St. Louis, Missouri

Barbara S. Norquist, MD
Assistant Professor of Obstetrics and Gynecology
University of Washington School of Medicine
Medical Director, Breast and Ovarian Cancer Prevention Program
Seattle Cancer Care Alliance
Seattle, Washington

Credit

1.00

Type

AMA PRA Category 1 Credit(s)TM

Accreditation Statement

The Johns Hopkins University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation Statement

The Johns Hopkins University School of Medicine designates this enduring activity for a maximum of 1.00 AMA PRA Category 1 CreditTM .  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The Johns Hopkins University School of Medicine takes responsibility for the content, quality, and scientific integrity of this CME activity.

American Nurses Credentialing Center (ANCC) accepts AMA PRA Category 1 CreditTM   from organizations accredited by the ACCME.

Disclosure of Unlabeled Use

In accordance with requirements of the FDA, the audience is advised that information presented in this continuing medical education activity may contain references to unlabeled or unapproved uses of drugs or devices. Please refer to the FDA-approved package insert for each drug/device for full prescribing/utilization information.

Disclaimer

The opinions and recommendations expressed by faculty and other experts whose input is included in this program are their own. Use of Johns Hopkins University School of Medicine name implies review of educational format design and approach. Please review the complete prescribing information of specific drugs or combination of drugs, including indications, contraindications, warnings and adverse effects before administering pharmacologic therapy to patients.

Instructions

To obtain credit, a score of 80% or better on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/Exam History, which you can access at any time.

Privacy Policy

The Office of Continuing Medical Education (CME) at the Johns Hopkins University School of Medicine is committed to protecting the privacy of its members and customers. Johns Hopkins University SOM CME maintains its Internet site as an information resource and service for physicians, other health professionals and the public.

Continuing Medical Education at the Johns Hopkins University School of Medicine will keep your personal and credit information confidential when you participate in a CME Internet based program. Your information will never be given to anyone outside of the Johns Hopkins University School of Medicine’s CME program. CME collects only the information necessary to provide you with the services that you request.

MCM privacy policy

myCME privacy policy

SYSTEM REQUIREMENTS

Hardware and Software Requirements
  • A computer with an internet connection
  • Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
  • Additional Software: Adobe Flash Player and/or an HTML 5 capable browser maybe required for video or audio playback. PowerPoint or Adobe Acrobat Reader may occasionally be required
Add to Queue